Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group

J. Minarik, L. Pour, V. Latal, T. Jelinek, J. Straub, A. Jungova, J. Radocha, P. Pavlicek, M. Stork, T. Pika, P. Krhovska, T. Popkova, F. Sedlak, I. Spicka, P. Jindra, V. Capounova, V. Maisnar, R. Hajek

. 2025 ; 25 (1) : 651. [pub] 20250409

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25016135

Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumumab (DRD), carfilzomib (KRD), and ixazomib (IRD), in relapsed/refractory multiple myeloma (RRMM).A retrospective registry-based study analyzed 538 RRMM patients undergoing therapy for their first to third relapse. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), with a matching-adjusted indirect comparisons (MAIC) employed to address cohort differences.ORR was highest for DRD at 91.4%, followed by KRD (89.6%) and IRD cohorts (Early-IRD: 79.6%, Late-IRD: 70.8%). Median PFS for DRD was greater at 23.64 months compared to KRD (16.52 months) and IRD groups (Early-IRD: 19.97 months, Late-IRD: 11.57 months). The MAIC confirmed better outcomes for the DRD regimen. High-risk features were not overcome by any of the LEN-based regimens.The findings underscore the superior efficacy of DRD in achieving sustained responses in RRMM patients. The composition of the cohort is a crucial factor, extending beyond selection criteria. This study highlights the importance of real-world evidence in assessing treatment modalities in clinical settings.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016135
003      
CZ-PrNML
005      
20250731091538.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-025-14087-y $2 doi
035    __
$a (PubMed)40205357
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. abretina@email.cz
245    10
$a Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group / $c J. Minarik, L. Pour, V. Latal, T. Jelinek, J. Straub, A. Jungova, J. Radocha, P. Pavlicek, M. Stork, T. Pika, P. Krhovska, T. Popkova, F. Sedlak, I. Spicka, P. Jindra, V. Capounova, V. Maisnar, R. Hajek
520    9_
$a Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumumab (DRD), carfilzomib (KRD), and ixazomib (IRD), in relapsed/refractory multiple myeloma (RRMM).A retrospective registry-based study analyzed 538 RRMM patients undergoing therapy for their first to third relapse. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), with a matching-adjusted indirect comparisons (MAIC) employed to address cohort differences.ORR was highest for DRD at 91.4%, followed by KRD (89.6%) and IRD cohorts (Early-IRD: 79.6%, Late-IRD: 70.8%). Median PFS for DRD was greater at 23.64 months compared to KRD (16.52 months) and IRD groups (Early-IRD: 19.97 months, Late-IRD: 11.57 months). The MAIC confirmed better outcomes for the DRD regimen. High-risk features were not overcome by any of the LEN-based regimens.The findings underscore the superior efficacy of DRD in achieving sustained responses in RRMM patients. The composition of the cohort is a crucial factor, extending beyond selection criteria. This study highlights the importance of real-world evidence in assessing treatment modalities in clinical settings.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $7 D009101
650    12
$a lenalidomid $x aplikace a dávkování $x terapeutické užití $7 D000077269
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a oligopeptidy $x aplikace a dávkování $7 D009842
650    _2
$a dospělí $7 D000328
650    _2
$a glycin $x analogy a deriváty $x aplikace a dávkování $7 D005998
650    _2
$a sloučeniny boru $x aplikace a dávkování $x terapeutické užití $7 D001896
650    12
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x terapeutické užití $7 D000911
650    _2
$a registrace $7 D012042
650    _2
$a chemorezistence $7 D019008
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic
700    1_
$a Latal, Vojtech $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Straub, Jan $u 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Jungova, Alexandra $u Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Pavlicek, Petr $u Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic
700    1_
$a Pika, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Krhovska, Petra $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Popkova, Tereza $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Sedlak, Frantisek $u 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Spicka, Ivan $u 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
700    1_
$a Jindra, Pavel $u Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Capounova, Vladimira $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Maisnar, Vladimir $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 25, č. 1 (2025), s. 651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40205357 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091533 $b ABA008
999    __
$a ok $b bmc $g 2366759 $s 1253260
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 1 $d 651 $e 20250409 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options